Consensus spike antigen for broad IBV vaccine development
Innovative IBV vaccine leveraging a consensus Spike antigen for broad protection across diverse strains, using the SpinyXpress platform for rapid, scalable production. Features injectable and needle-free formulations for flexible administration in poultry.
Overview
The Consensus Spike Antigen for Broad IBV Protection project aims to revolutionize the vaccination approach against Infectious Bronchitis Virus (IBV) in poultry. By using a consensus Spike antigen, the vaccine targets the virus's serotype diversity, providing broad protection across multiple strains. The SpinyXpress platform enables rapid and scalable production, allowing quick updates to the vaccine as new IBV variants emerge. This project offers two prototype formulations: an adjuvanted injectable subunit and a needle-free mucosal form, suited for mass administration via spray, drinking water, or in ovo, ensuring flexibility and safety.
Technical specifications
- Consensus Spike Antigen: Engineered for cross-protection against diverse IBV strains, aiming for ≥60% protection.
- SpinyXpress Platform: Facilitates rapid, scalable, and egg-free antigen production, crucial for fast adaptation to new virus variants.
- Prototype Formulations: Includes an injectable adjuvanted subunit and a needle-free mucosal option.
- Administration Methods: Designed for mass delivery through spray, drinking water, or in ovo methods.
Technology readiness level
The project is at Technology Readiness Level 3, with initial safety trials in chicks planned to evaluate tolerability. Successful vaccine candidates will undergo further immunogenicity studies to measure protective efficacy. The SpinyXpress platform's scalability will be demonstrated using small bioreactors to ensure readiness for high-volume production.
About La Trobe University
La Trobe University is a comprehensive public research university based in Melbourne, serving metropolitan and regional Australia through a multi‑campus footprint. Its Research and Innovation Precinct at the Bundoora campus enables industry co‑location, shared facilities, and streamlined access to talent. Collaborations with state agencies and Melbourne’s hospital network, plus a digital innovation hub and accelerator programs, provide pathways for prototyping, validation, and co‑development. Research is supported by competitive national funding, including the Australian Research Council and National Health and Medical Research Council, alongside industry partnerships and Cooperative Research Centre programs. A dedicated technology transfer office manages IP, licensing, and startup formation.
Inquire about this partnering listing
Looking for
Industry applications
delivered to your inbox.